California SB 1023 expands insurance coverage requirements for HIV prevention drugs and devices
August 30, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
Residents with private health insurance will gain easier access to HIV prevention medications and devices by removing administrative barriers like , while ensuring coverage is available through both medical and pharmacy benefit channels.
Potentially affected actors named in the source documents. Mention is not a position.
Health care service plans
They must update coverage policies to remove prior authorization and step therapy for HIV prevention products and ensure dual-benefit coverage.
Health insurers
They are prohibited from applying prior authorization or step therapy to medically necessary HIV prevention drugs and devices.
Private health insurance enrollees
They will have access to HIV prevention drugs and devices without prior authorization or step therapy requirements.
Last recorded activity August 30, 2026.
Introduced.
Summary
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Why It Matters
Residents with private health insurance will gain easier access to HIV prevention medications and devices by removing administrative barriers like , while ensuring coverage is available through both medical and pharmacy benefit channels.
Frequently Asked Questions
Does this bill apply to my Medi-Cal plan?
When do these changes take effect?
News Coverage
Bias ratings based on AllSides / Media Bias/Fact Check
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Removal of Utilization Management
The bill represents a shift from allowing limited utilization management (prior authorization/step therapy) to a total prohibition for HIV prevention products.
Connected Entities
Sources
openstates.org
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools